J.Jpn. Surg. Soc.. 90(9): 1451-1454, 1989
Report on the annual meeting
ADOPTIVE IMMUNOTHERAPY OF ADVANCED CANCER PATIENTS WITH IMMUNE RNA-SENSITIZED LYMPHOCYTES
|
First Department of Surgery, Hirosaki University School of Medicine, Hirosaki, Japan Matsuro Fukushima, Kazutoshi Takashima, Masato Tachibana, Takao Tsushima, Yuta Ogura, Yoshie Hasegawa, Hisaaki Koie |
Autologous (in some cases, allogeneic) lymphocytes were prepared with blood cell separator and incubated with I-RNA, then, returned to himself.
Twenty five cases of non-curatively resected gastric cancer (group A), 27 cases of stage II-IV of esophageal carcinoma (group B), 21 of lung cancer (group C), 14 of colorectal cancer (group D) and 37 cases with metastatic lesions (group E) were treated with this schedule.
Five year cumulative survival rate was 21％ in group A, 23％ in group B, 46％ in group C and 61％ in group D, respectively. One case of CR and 5 of PR were recognized in group E.
In many cases of the responder, lymphocyte count, ratio of Leu 4＋, 3a＋ subset in the peripheral bloods increased and skin reaction to autologous tumor cell extract, LAI and LMI became to positive. Interferon activity was also increased in the responder.
It was reported on the preliminary study of combination treatment with I-RNA sensitized lymphocytes and IL-2.
To read the PDF file you will need Adobe Reader installed on your computer.